Imatinib mesylate (Gleevec [STI-571]; Novartis Pharmaceuticals. Imatinib Mesylate Causes Hypopigmentation in the Skin
|
|
- Virginia Gilbert
- 5 years ago
- Views:
Transcription
1 2483 Imatinib Mesylate Causes Hypopigmentation in the Skin Anne S. Tsao, M.D. 1 Hagop Kantarjian, M.D. 2 Jorge Cortes, M.D. 2 Susan O Brien, M.D. 2 Moshe Talpaz, M.D. 3 1 Medical Oncology Fellowship Program, University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2 Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 3 Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas BACKGROUND. Imatinib mesylate is a tyrosine kinase inhibitor that targets the BCR-ABL protein in CML, c-kit (KIT) and platelet-derived growth factor receptors. In clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myelosuppression have been documented. METHODS. In this case series, the authors describe unique clinical findings of skin hypopigmentation in six patients with CML who were treated with imatinib mesylate. RESULTS. Most patients developed onset of skin hypopigmentation within the first month of treatment and all of the patients experienced additional drug toxicity. Despite patient susceptibility to toxicity, the presence of hypopigmentation did not appear to predict leukemic cell response or clinical outcome. All six patients established a hematologic response but only two patients had a complete cytogenetic response. Imatinib mesylate induced hypopigmentation also appeared to be reversible and potentially dose related. CONCLUSION. Skin hypopigmentation is a benign side effect from imatinib mesylate treatment that appears to be reversible upon discontinuation or dose reduction. Several lines of evidence have previously reported that KIT and its ligand stem cell factor (SCF) have a regulatory role in melanocyte development and survival, suggesting a rational mechanism of action for imatinib mesylate in the pathogenesis of hypopigmentation. The signal transduction mechanism currently is believed to involve SCF ligand binding of KIT and downstream activation of MAP kinase (Erk-2). Microphthalmia (Mi), a basic helix-loop-helix leucine zipper (bhl- HZip) transcription factor, is phosphorylated by MAP kinase at a serine residue (S73). Once phosphorylated, Mi transactivates the tyrosine pigmentation gene promoter and affects pigment production. Cancer 2003;98: American Cancer Society. KEYWORDS: imatinib mesylate, chronic myelogenous leukemia (CML), skin depigmentation, MAP kinase, microphthalmia. Address for reprints: Moshe Talpaz, M.D., Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030; Fax: (713) ; motalpaz@mdanderson.org Received June 10, 2003; revision received August 13, 2003; accepted August 27, Imatinib mesylate (Gleevec [STI-571]; Novartis Pharmaceuticals Corporation, East Hanover, NJ) is a tyrosine kinase inhibitor that targets the BCR-ABL protein in chronic myelogenous leukemia (CML), c-kit (KIT), and platelet-derived growth factor receptors. 1,2 In clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myelosuppression have been documented. The pathophysiology of diarrhea has been attributed to inhibition of the KIT receptor located on the interstitial cells of Cajal. 2 In the current case series, we describe clinical findings of skin hypopigmentation in six patients with CML who were treated with imatinib mesylate (Table 1). Several lines of evidence have previously reported that KIT and its ligand stem cell 2003 American Cancer Society DOI /cncr.11812
2 2484 CANCER December 1, 2003 / Volume 98 / Number 11 TABLE 1 Summary of Patient Characteristics Age (yrs) Gender Area of hypopigmentation Date of diagnosis of CML CML stage Imatinib mesylate start date Start dose Time to symptoms Dose change Effect on pigmentation CML response 63 F Total body 1997 Blast 11/ mg 3 mos Yes, held for 1 week 32 M Face, bilateral palms (patches up to 1 cm) 1997 Accelerated 4/ mg 1 year Yes, 58 M Face, torso, back 1997 Chronic 8/ mg Since start Yes, increased 77 F Face (patchy), 1995 Blast 12/ mg Since start Yes, upper chest, bilateral palms, upper arms 49 F General body 1999 Chronic 10/ mg Since start Yes, Darker skin during the 1 week Unknown Increased hypopigmentation Darker skin on lower dose Unknown Hematologic and cytogenetic disease 52 F Neck, hands, torso 2001 Chronic 7/ mg Since start No NA Hematologic and cytogenetic disease CML: chronic myelogenous leukemia; F: female; M: male; NA: not available. factor (SCF) play a regulatory role in melanocyte development and survival, suggesting a rational mechanism of action for imatinib mesylate in the pathogenesis of hypopigmentation. 3,4 Case Reports Patient 1 was a 63-year-old African-American female who was diagnosed in August 1997 with CML and treated sequentially with hydroxyurea, interferon- (IFN- ) and cytarabine (Ara-C), and pegylated interferon. In November 2000, she developed clonal evolution with blast crises and treatment with imatinib mesylate was initiated at a dose of 600 mg daily. The patient developed both a hematologic and cytogenetic disease within 3 months. During the initial 3 months of treatment, the patient experienced (NCI Common Toxicity Criteria) Grade 1 diarrhea, Grade 1 periorbital edema, and oral sores as well as total body hypopigmentation (Figs. 1,2). For 1 week of therapy, the patient had a gastrointestinal viral infection and did not receive imatinib mesylate. The patient reported darkening of her skin during that time. Patient 2 was a 32-year-old African-American male who was diagnosed in October 1997 with CML and previously was treated with hydroxyurea and interferon-. After 4 years of treatment, the patient progressed to accelerated-phase CML and treatment with 600 mg of imatinib mesylate daily was initiated in April A hematologic disease was ob- FIGURE 1. Pretreatment photograph of Patient 1, who had chronic myelogenous leukemia.
3 Imatinib Mesylate Changes Skin Pigmentation/Tsao et al FIGURE 2. (A,B) Skin pigmentation changes in Patient 1 after treatment with imatinib mesylate. tained within 1 month but the patient remained without a cytogenetic disease at the time of last follow-up. This patient had difficulty tolerating imatinib mesylate and required several breaks in treatment for Grade 2-3 myelosuppression (neutropenia and thrombocytopenia), Grade 1 muscle cramps, and periorbital edema. The patient noted that approximately 1 year after treatment with imatinib mesylate was initiated, a 1-cm patchy area of skin hypopigmentation appeared on his face and the extensor surface on his hands. Patient 3 was a 58-year-old African-American male who was diagnosed in 1997 with CML and was heavily pretreated before imatinib therapy with interferon-, combined interferon- and Ara-C, hydroxyurea and anagrelide, and 9-nitrocamptothecin. Although still in chronic phase, he had evidence of clonal evolution and treatment with 600 mg of daily imatinib mesylate was initiated in August A hematologic disease and partial cytogenetic disease were achieved within 1 year. The patient noted hypopigmentation to his face and clothing-covered areas at the initiation of therapy. Additional side effects experienced were Grade 0-1 nausea and emesis, Grade 1 periorbital edema, Grade 1 muscle cramps, and Grade 1 anemia. During treatment, the patient s daily dose of imatinib was increased to 800 mg and an additional lightening of the patient s hypopigmented areas occurred. Patient 4 was a 77-year-old African-American female diagnosed in 1995 with CML and treated with interferon- and hydroxyurea. After progressing to blast crises in December 2000, treatment was initiated with 600 mg of daily imatinib mesylate and within 3 months, the patient noticed patches of skin hypopigmentation on the face, upper arms, palms, and torso. A hematologic disease was achieved (but not a cytogenetic disease ) after 1 year of therapy. During treatment, the patient developed Grade 3 myelosuppression, Grade 2 diarrhea, and Grade 2 nausea and emesis leading to a dose reduction to 400 mg. This dose reduction led to darkening of the patient s hypopigmented areas. Patient 5 was a 49-year-old African-American female who was diagnosed with CML in 1999 and treated with interferon-, pegylated interferon, hy-
4 2486 CANCER December 1, 2003 / Volume 98 / Number 11 droxyurea, and anagrelide. After failure to obtain cytogenetic disease, treatment with imatinib mesylate at a dose of 400 mg daily was initiated in October 2000 and the patient achieved a hematologic disease. The patient noticed general body skin lightening at the time the imatinib mesylate treatment began. Because of Grade 3 myelosuppression, the dose was reduced to 300 mg but the patient did not report any changes in her skin coloring. Patient 6 was a 52-year-old African-American female who was diagnosed with chronic phase CML in 2001 and treated with a few weeks of hydroxyurea. The patient was then treated with 800 mg of daily imatinib mesylate and within 1 month noticed hypopigmentation on her hands, neck, and torso. The patient only experienced Grade 1 periorbital edema, diarrhea, leg cramps, and anemia and had not required any dose reductions at the time of last follow-up. She achieved complete hematologic and cytogenetic disease s with this dose regimen. DISCUSSION Although the current case series had a small number of patients, some general trends are notable. The majority of the patients noticed the pigmentation changes at the time treatment with imatinib mesylate was initiated (within 1 month) and had persistent hypopigmentation during therapy. Also, all the patients experienced additional imatinib mesylate toxicities, five patients experienced myelosuppression (Grade 1-3), four reported diarrhea (Grade 1-2), four had muscle cramps (Grade 1), three experienced nausea and emesis (Grade 1), five reported periorbital edema (Grade 1), and one patient experienced mouth sores and a loss of taste. Four of the patients required dose reductions or interruptions of the imatinib mesylate therapy because of myelosuppression and gastrointestinal symptoms. Despite patient susceptibility to drug toxicity, the presence of hypopigmentation does not appear to predict leukemic cell response or clinical outcome. All six of the CML patients in the current study achieved a hematologic response but only two patients were reported to have achieved a complete cytogenetic response. To our knowledge, there is one reported case of imatinib mesylate-induced hypopigmentation in the literature that occurred in a Caucasian male with involvement of the distal aspects of both hands and the penis. 5 Although all the patients in the current study were of African-American ethnicity, this report indicates that the skin toxicity is not specific to one ethnic background and, most likely, the skin changes are more noticeable and therefore more likely to be reported among patients with darker skin. Imatinib mesylate-induced hypopigmentation appears to be reversible and potentially dose related. In the two cases of dose interruption or reduction reported in the current study, patients reported darkening of their skin pigmentation. In the one patient in whom the dose was interrupted, reinitiation of therapy reversed the skin darkening and led to a light skin tone similar to the color found prior to the dose interruption. The converse also appears to occur with dose escalation; in the 1 patient who was treated with 800 mg of imatinib mesylate, an increase in the degree of skin hypopigmentation was documented. The receptor KIT and its ligand SCF play a critical role in the development and maintenance of human melanocytes. During embryogenesis, SCF and KIT direct melanoblast migration from the neural tube to the skin of the embryo and, in the postnatal period, maintain the survival of melanocytes. 4 Although to our knowledge the exact mechanism by which this occurs is unclear at the present time, melanocyte homeostasis and differentiation also have been attributed to the SCF/KIT pathway. This is supported by the observation that human mutations in the encoded tyrosine kinase region of KIT have been shown to cause piebaldism, an autosomal dominant disorder characterized by white hair and hypopigmented skin patches on the forehead, torso, and extremities. 6,7 In addition, murine models with human xenograft skin were subjected to KIT inhibitory antibody (K44.2), which led to melanocyte loss and a decrease in differentiation antigens and melanocyte dendritic processes. Prolonged KIT inhibition led to melanocyte apoptosis. This finding provides in vitro evidence of a critical role for SCF/KIT in the homeostasis and survival of human melanocytes. 3 The signal transduction mechanism currently is believed to involve SCF ligand binding of KIT and downstream activation of MAP kinase (Erk-2). Microphthalmia (Mi), a basic, helix-loop-helix, leucine zipper (bhlhzip) transcription factor, is phosphorylated by MAP kinase at a serine residue (S73). Once phosphorylated, Mi transactivates the tyrosine pigmentation gene promoter and affects pigment production. 8 Heterozygous Mi mutations in humans is reported to cause type IIA Waardenburg syndrome. 8,9 Recommendations Adverse effects from skin hypopigmentation include photosensitivity. The majority of patients in the current study developed hypopigmentation changes in sun-exposed areas and in two cases sunburn was experienced. Treatment recommendations therefore include avoidance of sun exposure and the use of sun block. Although the emotional impact of the skin
5 Imatinib Mesylate Changes Skin Pigmentation/Tsao et al changes can be significant, to our knowledge few options are available to alter the side effect. Prior studies have evaluated the use of tretinoin treatments on hypopigmented macules in the photodamaged skin of elderly patients. Four months of treatment reportedly led to a partial restoration of pigmentation. 10 This is not currently recommended but can be considered an option if the emotional impact is believed to affect the patient s quality of life. Other additional options include the use of tinted cosmetic products or selftanning topical preparations. Although biopsies were considered in the current series, we were unable to ethically justify subjecting these patients to the procedure. This skin toxicity, although cosmetically a problem, does not pose a substantial medical hazard. However, we would recommend conducting future translational prospective studies with skin biopsies to further evaluate and confirm the mechanism of action for this skin toxicity. REFERENCES 1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2: Savage DG, Antman KH. Imatinib mesylate a new oral targeted therapy. N Engl J Med. 2002;346: Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998;111: Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol. 1999;113: Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol. 2002;20: Nomura K, Hatayama I, Narita T, Kaneko T, Shiraishi M. A novel KIT gene missense mutation in a Japanese family with piebaldism. J Invest Dermatol. 1998;111: Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44: Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-kit signalling in melanocytes. Nature. 1998;391: Wu M, Hemesath TJ, Takemoto CM, et al. c-kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000;14: Pagnoni A, Kligman AM, Sadiq I, Stoudemayer T. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol. 1999;79:
Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationIMATINIB MESYLATE (Gleevec or Glivec, Novartis,
Imatinib Treatment: Specific Issues Related to Safety, Fertility, and Pregnancy Martee L. Hensley and John M. Ford Imatinib (Gleevec) (formerly STI571) has demonstrated high levels of efficacy in chronic
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationThe New England Journal of Medicine
ACTIVITY OF A SPECIFIC INHIBITOR OF THE BCR-ABL TYROSINE KINASE IN THE BLAST CRISIS OF CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA WITH THE PHILADELPHIA CHROMOSOME BRIAN J. DRUKER, M.D.,
More informationTalpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:
References Sprycel Talpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:2531-2541. National Comprehensive Cancer Network. Clinical Practice
More informationGleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More informationImatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
ORIGINAL ARTICLE Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia Bahoush Gr, 1 Alebouyeh M, 2 Vossough P 1 1 Pediatric Hematology-Oncology Department, Ali-Asghar Children's Hospital,
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationAn update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
Singapore Med J 2012; 53(1) : 57 An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia Bee PC 1, MD, MMed, Gan GG 1, MBBS, FRCP, Tai YT 1, MBBS,
More informationSTI571: Targeting BCR-ABL as Therapy for CML
STI571: Targeting BCR-ABL as Therapy for CML MICHAEL J. MAURO, BRIAN J. DRUKER Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, Oregon, USA Key
More informationOriginal Article. Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
Original Article Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients Ali M.Jawad * CABM FRCP (Edin) Batool A.G. Yassin** FICM.CM Nabeel Salman*** FRCP (Edin) Ali Al-Ameri**** CABM
More informationGLEEVEC (imatinib mesylate) Capsules FACT SHEET
Health Canada Santé Canada GLEEVEC (imatinib mesylate) Capsules FACT SHEET CONDITIONAL APPROVAL OF GLEEVEC This fact sheet notifies the Canadian public that Health Canada has issued a conditional marketing
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationTKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology
TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients Moustafa Sameer Hematology Medical Advsior,Novartis oncology Introduction In people with chronic myeloid leukemia, A
More information"Molecular Monitoring Strategies to Track Response to BCR-ABL Kinase Inhibitors in CML"
Association of Molecular Pathology USCAP Companion Meeting Sunday, February 12, 2006 7:00 PM Dan Jones, MD, PhD Associate Professor Medical Director, Molecular Diagnostic Laboratory Division of Pathology
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationCIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationFrontiers in Cancer Therapy. John Glod, M.D., Ph.D.
Frontiers in Cancer Therapy John Glod, M.D., Ph.D. September 15, 2017 Objectives The Past: Alkylating agents The Present: Tyrosine Kinase Inhibitors The Future: Gene Expression, Metabolic cancers, CAR
More informationImmune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia
Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationThe New England. Copyright 2001 by the Massachusetts Medical Society
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 344 A PRIL 5, 2001 NUMBER 14 EFFICACY AND SAFETY OF A SPECIFIC INHIBITOR OF THE BCR-ABL TYROSINE KINASE IN
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationNilotinib in Imatinib-Resistant CML and Philadelphia Chromosome Positive ALL
The new england journal of medicine original article Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome Positive ALL Hagop Kantarjian, M.D., Francis Giles, M.D., Lydia Wunderle, M.D., Kapil
More informationThe Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon
The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML), improving the prognosis to such an extent that the
More informationIN PHILADELPHIA CHROMOSOME positive (Ph )
Targeted Therapies in the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Dieter Hoelzer, Nicola Gökbuget, and Oliver G. Ottmann Imatinib mesylate (Gleevec, Novartis Pharmaceuticals
More informationChronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018
Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 00 by the Massachusetts Medical Society VOLUME 346 F EBRUARY 8, 00 NUMBER 9 HEMATOLOGIC AND CYTOGENETIC RESPONSES TO IMATINIB MESYLATE IN CHRONIC MYELOGENOUS
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1037-6 Program Prior Authorization/Notification Medication Gleevec (imatinib mesylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationResponse to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil
Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil C.A.P. Silveira 1, M.B. Daldegan 1 and I. Ferrari 2 1 Núcleo de
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationChronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE
Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE If searched for the ebook by DEISSEROTH Chronic Myelogenous Leukemia (Hematology) in pdf format, in that case you come on to correct
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationSynribo. Synribo (omacetaxine mepesuccinate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.31 Subject: Synribo Page: 1 of 5 Last Review Date: December 3, 2015 Synribo Description Synribo (omacetaxine
More informationA Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: CABL001X2101 Previous Study Return to List
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationApproval based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer
Avillion Announces US Approval of Pfizer s BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) Approval based on the successful BFORE Phase 3 study
More informationHematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients
ORIGINAL ALBANIAN MEDICAL RESEARCH JOURNAL Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients Dorina Roko 1, Anila Babameto-Laku
More informationResearch Article The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
Transplantation Volume 2009, Article ID 357093, 4 pages doi:10.1155/2009/357093 Research Article The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow
More informationChronic myelogenous leukemia (CML) is a myeloproliferative disorder
437 Chronic Myelogenous Leukemia: A Review and Update of Therapeutic Strategies Guillermo Garcia-Manero, M.D. 1 Stefan Faderl, M.D. 1 Susan O Brien, M.D. 1 Jorge Cortes, M.D. 1 Moshe Talpaz, M.D. 2 Hagop
More informationManaging Relapse of CML Using Therapeutic Imatinib Plasma Level
H&0 CLINICAL CASE STUDIES Managing Relapse of CML Using Therapeutic Imatinib Plasma Level Adedayo A. Onitilo, MD, MSCR, FACP 1 Jessica M. Engel, MSN, FNP-BC 2 Department of Hematology/Oncology, 1 Marshfield
More informationBL-8040: A Novel CXCR4 Antagonist
BL-8040: A Novel CXCR4 Antagonist December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," plans,
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase Warren E, Ward S, Gordois A, Scuffham P Record Status This is a critical abstract of an
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationChronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors
17 (Supplement 10): x274 x279, 2006 doi:10.1093/annonc/mdl273 Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors A. Hochhaus III Medizinische Klinik, Medizinische Fakultät Mannheim
More informationNCCP Chemotherapy Protocol. Bosutinib Monotherapy
Bosutinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous
More informationMolecular Hematopathology Leukemias I. January 14, 2005
Molecular Hematopathology Leukemias I January 14, 2005 Chronic Myelogenous Leukemia Diagnosis requires presence of Philadelphia chromosome t(9;22)(q34;q11) translocation BCR-ABL is the result BCR on chr
More informationCancer and Tyrosine Kinase Inhibition
Cancer and Tyrosine Kinase Inhibition 1 Motivation (1) In first world countries cancer is the second most common cause of death after cardiovascular diseases. For most tumors, treatment is limited to surgery,
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationEFFECT OF AGE AND SEX UNDER IMATINIB MESYLATE THERAPY ON CHRONIC MYELOID LEUKAEMIA PATIENTS: A PILOT STUDY FROM INDIA
IJPSR (2017), Vol. 8, Issue 4 (Research Article) Received on 22 July, 2016; received in revised form, 21 November, 2016; accepted, 08 January, 2017; published 01 April, 2017 EFFECT OF AGE AND SEX UNDER
More informationA medicine to block the amount of acid produced in the stomach (H2 blocker): about 10 hours before about 2 hours after
TRACKING JOURNAL YOUR TRACKING JOURNAL Throughout your treatment with TASIGNA (nilotinib), your doctor will prescribe regular tests to see if your treatment is working. It s important to keep up with your
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 March 2007 SPRYCEL 20 mg, film-coated tablet, blister (377 637-9) SPRYCEL 20 mg, film-coated tablet, bottle (377
More informationOMONDI OGUDE MEDICAL ONCOLOGY
OMONDI OGUDE MEDICAL ONCOLOGY Personalized medicine (Targeted therapy) In recent years there s been a move from conventional cytotoxic therapy to more targeted therapy Mostly due to the rapid pace of
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationResults of a Phase II Trial Testing Interferon-Alpha 2b and Cytarabine in Children and Adolescents With Chronic Myelogenous Leukemia
Pediatr Blood Cancer 2006;47:555 559 Results of a Phase II Trial Testing Interferon-Alpha 2b and Cytarabine in Children and Adolescents With Chronic Myelogenous Leukemia Frédéric Millot, MD, 1 * Joelle
More informationOncology Hematology and Cell Therapy, CHU La Milétrie, Poitiers, France
The Oncologist Breast Cancer Indications for Imatinib Mesylate Therapy and Clinical Management FRAÇOIS GUILHOT Oncology Hematology and Cell Therapy, CHU La Milétrie, Poitiers, France Key Words. Imatinib
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationKirsten C. Webb, 1 Magdalena Harasimowicz, 2 Monica Janeczek, 2 Jodi Speiser, 3 James Swan, 1 and Rebecca Tung Introduction. 2.
Hindawi Case Reports in Dermatological Medicine Volume 2017, Article ID 9359086, 5 pages https://doi.org/10.1155/2017/9359086 Case Report Development of Asymmetric Facial Depigmentation in a Patient Treated
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationImatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients
http://dx.doi.org/10.4046/trd.2011.71.3.210 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2011;71:210-215 CopyrightC2011. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationChronic myelogenous leukemia (CML) is a slowprogressing
At a Glance Practical Implications p e148 Author Information p e151 Full text and PDF Web exclusive Patterns of Specific Testing for Patients With Chronic Myelogenous Leukemia Original Research Allison
More informationDynamics of Chronic Myeloid Leukemia Supplementary Online Material
Dynamics of Chronic Myeloid Leukemia Supplementary Online Material Franziska Michor, Timothy P. Hughes, Yoh Iwasa, Susan Branford, Neil P. Shah, Charles L. Sawyers & Martin A. Nowak The basic model. Our
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationGLEEVEC (imatinib mesylate) PATIENT RESOURCES
Talking with your doctor about Ph+ CML and its treatment When you have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), it s important to take an active role in your care. You will
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Received: 13 December 2017 Accepted: 17 December 2017 DOI: 10.1002/ajh.25011 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
More informationCHRONIC MYELOID LEUKEMIA. Dr.M SAI SRAVANTHI POST GRADUATE DEPT OF GENERAL MEDICINE KAMINENI INSTITUTE OF MEDICAL SCIENCES
CHRONIC MYELOID LEUKEMIA Dr.M SAI SRAVANTHI POST GRADUATE DEPT OF GENERAL MEDICINE KAMINENI INSTITUTE OF MEDICAL SCIENCES CHRONIC MYELOID LEUKEMIA INCIDENCE The incidence of CML is 1.5 per 100,000 people
More informationAccepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
More informationUpdate on Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia
Update on Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia Chronic myelogenous leukemia (CML), a hematologic malignancy associated with a chromosomal mutation commonly known as the Philadelphia
More information35 Current Trends in the
35 Current Trends in the Management of Chronic Myelogenous Leukemia Abstract: CML is a hematopoietic stem cell disease which is characterized by the presence of Philadelphia chromosome (Ph-chromosome)
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationKinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
International journal of Biomedical science ORIGINAL ARTICLE Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
More informationClinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Tasigna) Reference Number: CP.CPA.162 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationWafaa H. El-Metnawy 1, Mervat M. Mattar 2, Yasser H. El-Nahass 3, Mohamed A. Samra 4, Hala M. Abdelhamid 2, Raafat M. AbdlFattah 4, Ahmad R.
International journal of Biomedical science ORIGINAL ARTICLE Predictive Value of Pretreatment BCR-ABL IS Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic
More informationVYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA
VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA Sarah Mae Rogado PharmD Candidate 2017 Preceptors: Rozena Varghese, PharmD, CMPP; Rachel Brown, PharmD MedVal Scientific Information
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationThe biology of chronic myeloid leukaemia
The biology of chronic myeloid leukaemia Graduate Program Course: Biology of cancer April 2007 Myeloproliferative disorders Clonal disorders of haemopoiesis that arise in a haemopoietic stem cell or early
More informationDETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA
Analele Ştiinţifice ale Universităţii Alexandru Ioan Cuza, Secţiunea Genetică şi Biologie Moleculară, TOM XIV, 2013 DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationIt is also an option for those with Ph+ve CML who initially present in accelerated phase or with blast crisis 1.
Imatinib (Glivec ) Indications 1 Imatinib is recommended as first line treatment for people with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase 1. It is also an
More informationIclusig. Iclusig (ponatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Subject: Iclusig Page: 1of 6 Last Review Date: June 22, 2018 Iclusig Description Iclusig (ponatinib)
More information